Combination therapy with bicalutamide and everolimus resulted in promising responses in a phase II trial of patients with castration-resistant prostate cancer, though a substantial proportion of patients experienced everolimus-related toxicities.
Results of a phase II randomized trial found that combining a short course of androgen deprivation therapy with bevacizumab improved relapse-free survival in men with hormone-sensitive prostate cancer.
In this video, Dr. Nicholas David James discusses the results of the STAMPEDE trial, which tested front-line docetaxel combined with hormonal therapy in patients with advanced, hormone-naive prostate cancer.
Dr. Morris discusses results and implications of the CHAARTED trial, which studied the survival impact of androgen deprivation therapy (ADT) plus docetaxel vs ADT alone for hormone-sensitive newly metastatic prostate cancer.
Nancy Dawson, MD discusses PSA dynamics: the significance of PSA levels and PSA doubling time—the marker which currently provides the most information—and their usefulness in predicting metastatic disease and in counseling patients on their prognosis.